[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
October 11, 1995

Treatment of Hyperlipidemia in Women

Author Affiliations

From the Department of Medicine, University of California San Francisco/Mount Zion, (Dr Walsh), the Veterans Affairs Medical Center, General Internal Medicine Section, San Francisco (Dr Grady), and Department of Epidemiology and Biostatistics, University of California, San Francisco (Dr Grady).

JAMA. 1995;274(14):1152-1158. doi:10.1001/jama.1995.03530140064034

Objective.  —To assess the evidence that lipid lowering prevents coronary heart disease (CHD) events in women.

Data Sources.  —English-language literature assessing the effects of cholesterol lowering with dietary and/or drug interventions as primary or secondary prevention on CHD events in women.

Main Outcome Measures.  —Coronary heart disease and total mortality were the primary outcomes assessed. Angiographic regression of coronary atherosclerosis was a secondary outcome.

Study Selection, Data Extraction, and Data Synthesis.  —All nine of the identified studies that met the criteria were included. Relative risks for CHD and total mortality were calculated from available data. Summary relative risks were calculated using meta-analytic techniques.

Conclusions.  —There is no evidence from primary prevention trials that cholesterol lowering affects total mortality in healthy women, although the available data are limited. Limited evidence suggests that treatment of hypercholesterolemia in women with coronary disease may decrease CHD mortality. Future research should address the role of dietary and other nondrug treatment of hypercholesterolemia in women at high risk for CHD.(JAMA. 1995;274:1152-1158)